Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study

Prostate

Volumn 77, Issue 1, 2017, Pages 33-40

  Maughan, Benjamin L ^a   Luber, Brandon ^a   Nadal, Rosa ^a   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

abiraterone; enzalutamide; metastatic castration resistant prostate cancer; sequence

Indexed keywords

ABIRATERONE; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84994559182     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23246     Document Type: Article

References (13)

1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM. Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21):1995–2005.
2. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI. Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368(2):138–148.
3. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13):1187–1197.
4. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371(5):424–433.
5. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 2015; 67(1):23–29.
6. Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 2014; 74(13):1278–1285.
7. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371(11):1028–1038.
8. Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother 2015; 16(10):1521–1537.
9. Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: Retrospective analysis of real-world data. Cancer Med 2016; 5(2):182–191.
10. Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 2015; 16(6):e279–e292.
11. Lebdai S, Basset V, Branchereau J, de la Taille A, Flamand V, Lebret T, Murez T, Neuzillet Y, Ploussard G, Audenet F. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? World J Urol 2016; 34(5):617–624.
12. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncology 2015; 1(5):582–591.
13. Scher HI, Graf R, Louw J, Jendrisak A, Johnson A, Greene S, Rodriguez A, Schreiber N, McLaughlin B, Dugan L, Fleisher M, Lee J, Wang Y, Marrinucci D, Landers M, Dittamore RV. Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients. J Clin Oncol 2016; (suppl 2S; abstr 163) 34.